Skip to main content
. 2021 Mar 12;23(5):360. doi: 10.3892/mmr.2021.11999

Figure 4.

Figure 4.

Effect of LAMP2A expression on the sensitivity to 5-FU in human CRC cell line. (A) Cellular viability of different drug treatments in shLAMP2A-modified DLD-1-R or LAMP2A-modified DLD-1 cells. (B) Expression of associated proteins was visualized by western blotting in shLAMP2A-modified DLD-1-R cells or in LAMP2A-modified DLD-1 cells. (C) Apoptosis and (D) migration and invasion in shLAMP2A-modified DLD-1-R cells or in LAMP2A-modified DLD-1 cells (×10 magnification). The data represent the mean ± standard deviation from three independent experiments. *P<0.05, **P<0.01. LAMP2A, lysosome-associated membrane protein 2A; 5-FU, 5-fluorouracil; CRC, colorectal cancer; sh, short hairpin; R, resistance; NC, negative control; 5-FU, 10 mM; 5-FU; OXA, 10 mM oxaliplatin; FOX, 10 mM 5-FU + 10 mM oxaliplatin; PLD2, phospholipase D2.